Proteolysis targeting chimeras (PROTAC) for targeting Alzheimer’s disease
Open Access
- 27 May 2026
- journal article
- Published by Springer Nature in Discover Neuroscience
- Vol. 21 (1)
Abstract
No abstract availableThis publication has 167 references indexed in Scilit:
- Plasma p‐tau217 predicts PET‐based pathological staging for precision Alzheimer disease assessmentAlzheimer's & Dementia, 2026
- Post‐Covid Alzheimer and Its Remediation via PROTACs Therapy: A Comprehensive ReviewHealth Science Reports, 2025
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future DirectionsMedcomm, 2025
- 2024 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2024
- Targeted Development of Pyrazoline Derivatives for Neurological Disorders: A ReviewChemistrySelect, 2024
- TTC3-Mediated Protein Quality Control, A Potential Mechanism for Cognitive ImpairmentCellular and Molecular Neurobiology, 2021
- PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug DiscoveryBioEssays, 2018
- Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosisActa Neuropathologica, 2015
- Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1αAngewandte Chemie International Edition, 2012
- Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and TherapeuticsNeurochemical Research, 2006